S&P 500   2,527.06 (+2.29%)
DOW   21,398.15 (+2.17%)
QQQ   186.07 (+2.06%)
AAPL   243.83 (+1.21%)
FB   157.62 (-1.24%)
MSFT   154.09 (+1.30%)
GOOGL   1,110.93 (+0.80%)
AMZN   1,909.60 (+0.10%)
CGC   13.84 (+1.91%)
NVDA   254.54 (+4.72%)
BABA   188.97 (+0.75%)
MU   40.86 (+2.41%)
GE   6.90 (-1.99%)
TSLA   452.89 (-5.96%)
AMD   44.26 (+1.37%)
T   28.78 (+2.60%)
ACB   0.83 (+2.46%)
F   4.34 (-1.36%)
NFLX   370.31 (+1.71%)
BAC   20.58 (+4.05%)
GILD   77.38 (+6.70%)
PRI   82.63 (-1.82%)
DIS   96.85 (+2.03%)
S&P 500   2,527.06 (+2.29%)
DOW   21,398.15 (+2.17%)
QQQ   186.07 (+2.06%)
AAPL   243.83 (+1.21%)
FB   157.62 (-1.24%)
MSFT   154.09 (+1.30%)
GOOGL   1,110.93 (+0.80%)
AMZN   1,909.60 (+0.10%)
CGC   13.84 (+1.91%)
NVDA   254.54 (+4.72%)
BABA   188.97 (+0.75%)
MU   40.86 (+2.41%)
GE   6.90 (-1.99%)
TSLA   452.89 (-5.96%)
AMD   44.26 (+1.37%)
T   28.78 (+2.60%)
ACB   0.83 (+2.46%)
F   4.34 (-1.36%)
NFLX   370.31 (+1.71%)
BAC   20.58 (+4.05%)
GILD   77.38 (+6.70%)
PRI   82.63 (-1.82%)
DIS   96.85 (+2.03%)
S&P 500   2,527.06 (+2.29%)
DOW   21,398.15 (+2.17%)
QQQ   186.07 (+2.06%)
AAPL   243.83 (+1.21%)
FB   157.62 (-1.24%)
MSFT   154.09 (+1.30%)
GOOGL   1,110.93 (+0.80%)
AMZN   1,909.60 (+0.10%)
CGC   13.84 (+1.91%)
NVDA   254.54 (+4.72%)
BABA   188.97 (+0.75%)
MU   40.86 (+2.41%)
GE   6.90 (-1.99%)
TSLA   452.89 (-5.96%)
AMD   44.26 (+1.37%)
T   28.78 (+2.60%)
ACB   0.83 (+2.46%)
F   4.34 (-1.36%)
NFLX   370.31 (+1.71%)
BAC   20.58 (+4.05%)
GILD   77.38 (+6.70%)
PRI   82.63 (-1.82%)
DIS   96.85 (+2.03%)
S&P 500   2,527.06 (+2.29%)
DOW   21,398.15 (+2.17%)
QQQ   186.07 (+2.06%)
AAPL   243.83 (+1.21%)
FB   157.62 (-1.24%)
MSFT   154.09 (+1.30%)
GOOGL   1,110.93 (+0.80%)
AMZN   1,909.60 (+0.10%)
CGC   13.84 (+1.91%)
NVDA   254.54 (+4.72%)
BABA   188.97 (+0.75%)
MU   40.86 (+2.41%)
GE   6.90 (-1.99%)
TSLA   452.89 (-5.96%)
AMD   44.26 (+1.37%)
T   28.78 (+2.60%)
ACB   0.83 (+2.46%)
F   4.34 (-1.36%)
NFLX   370.31 (+1.71%)
BAC   20.58 (+4.05%)
GILD   77.38 (+6.70%)
PRI   82.63 (-1.82%)
DIS   96.85 (+2.03%)
Log in

NASDAQ:ICAD - iCAD Stock Price, Forecast & News

$7.29
+0.66 (+9.95 %)
(As of 04/2/2020 04:00 PM ET)
Today's Range
$6.61
Now: $7.29
$7.46
50-Day Range
$6.94
MA: $10.64
$14.42
52-Week Range
$4.46
Now: $7.29
$15.31
Volume224,637 shs
Average Volume439,340 shs
Market Capitalization$154.33 million
P/E RatioN/A
Dividend YieldN/A
Beta0.8
iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer in the United States and internationally. It operates through two segments, Cancer Detection and Cancer Therapy. The company provides electronic brachytherapy (eBX) products, including Axxent eBx systems for the treatment of early stage breast cancer, endometrial cancer, cervical cancer, and skin cancer, as well as for treating other cancers or conditions where radiation therapy is indicated comprising intraoperative radiation therapy. It also offers digital mammography computer-aided detection (CAD) products, such as advanced image analysis and workflow solutions in breast imaging, which include PowerLook Mammo Detection, which detects and identifies suspicious masses and micro-calcifications; and PowerLook Advanced Mammography Platform, a computer server residing on a customer's network that receives patient studies from the imaging modality, performs CAD and density assessment analysis, and sends the CAD results to picture archiving and communication system and/or review workstations. In addition, the company's digital mammography CAD products comprise magnetic resonance imaging products to detect breast and prostate cancer; breast tomosynthesis systems; and advanced image analysis and workflow solutions in computed tomography (CT) colonography, including VeraLook that supports the detection of colonic polyps in conjunction with CT colonography. It serves hospitals, ambulatory care centers and free standing radiation oncology facilities, and other office-based uses through sales organizations, as well as through various original equipment manufacturer partners, distributors, and resellers. iCAD, Inc. has a strategic partnership agreement with Invivo Corp. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was founded in 1984 and is headquartered in Nashua, New Hampshire.
Read More

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorComputer and Technology
Current SymbolNASDAQ:ICAD
CUSIPN/A
Phone603-882-5200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$31.34 million
Book Value$0.26 per share

Profitability

Net Income$-13,550,000.00

Miscellaneous

Employees95
Market Cap$154.33 million
Next Earnings Date5/5/2020 (Estimated)
OptionableOptionable

Receive ICAD News and Ratings via Email

Sign-up to receive the latest news and ratings for ICAD and its competitors with MarketBeat's FREE daily newsletter.


iCAD (NASDAQ:ICAD) Frequently Asked Questions

How has iCAD's stock been impacted by COVID-19 (Coronavirus)?

iCAD's stock was trading at $11.12 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ICAD stock has decreased by 34.4% and is now trading at $7.29. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of iCAD?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for iCAD in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for iCAD.

When is iCAD's next earnings date?

iCAD is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for iCAD.

How were iCAD's earnings last quarter?

iCAD Inc (NASDAQ:ICAD) posted its earnings results on Thursday, February, 27th. The technology company reported ($0.10) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.12) by $0.02. The technology company had revenue of $9.38 million for the quarter. iCAD had a negative net margin of 43.24% and a negative return on equity of 92.89%. View iCAD's earnings history.

What price target have analysts set for ICAD?

4 analysts have issued 1-year price objectives for iCAD's stock. Their forecasts range from $10.00 to $15.00. On average, they expect iCAD's stock price to reach $13.50 in the next twelve months. This suggests a possible upside of 85.2% from the stock's current price. View analysts' price targets for iCAD.

Has iCAD been receiving favorable news coverage?

News headlines about ICAD stock have been trending very negative this week, according to InfoTrie. The research group identifies positive and negative news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. iCAD earned a media sentiment score of -3.3 on InfoTrie's scale. They also gave news coverage about the technology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news aboutiCAD.

Are investors shorting iCAD?

iCAD saw a decrease in short interest in the month of February. As of February 28th, there was short interest totaling 455,900 shares, a decrease of 46.4% from the February 13th total of 851,200 shares. Based on an average trading volume of 230,900 shares, the days-to-cover ratio is presently 2.0 days. Approximately 2.6% of the company's shares are short sold. View iCAD's Current Options Chain.

Who are some of iCAD's key competitors?

What other stocks do shareholders of iCAD own?

Who are iCAD's key executives?

iCAD's management team includes the following people:
  • Ms. Stacey M. Stevens, Pres (Age 51)
  • Mr. Michael S. Klein, Exec. Chairman & CEO (Age 65)
  • Mr. R. Scott Areglado, VP, Corp. Controller & Interim CFO (Age 55)
  • Mr. Jonathan Go, Chief Technology Officer (Age 56)
  • Ms. Annette L. Heroux, VP of Admin. (Age 62)

What is iCAD's stock symbol?

iCAD trades on the NASDAQ under the ticker symbol "ICAD."

How do I buy shares of iCAD?

Shares of ICAD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is iCAD's stock price today?

One share of ICAD stock can currently be purchased for approximately $7.29.

How big of a company is iCAD?

iCAD has a market capitalization of $154.33 million and generates $31.34 million in revenue each year. The technology company earns $-13,550,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis. iCAD employs 95 workers across the globe. View additional information about iCAD.

What is iCAD's official website?

The official website for iCAD is http://www.icadmed.com/.

How can I contact iCAD?

iCAD's mailing address is 98 SPIT BROOK ROAD SUITE 100, NASHUA NH, 03062. The technology company can be reached via phone at 603-882-5200 or via email at [email protected]


MarketBeat Community Rating for iCAD (NASDAQ ICAD)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  195 (Vote Outperform)
Underperform Votes:  192 (Vote Underperform)
Total Votes:  387
MarketBeat's community ratings are surveys of what our community members think about iCAD and other stocks. Vote "Outperform" if you believe ICAD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ICAD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel